JP2001508441A5 - - Google Patents

Download PDF

Info

Publication number
JP2001508441A5
JP2001508441A5 JP1998530901A JP53090198A JP2001508441A5 JP 2001508441 A5 JP2001508441 A5 JP 2001508441A5 JP 1998530901 A JP1998530901 A JP 1998530901A JP 53090198 A JP53090198 A JP 53090198A JP 2001508441 A5 JP2001508441 A5 JP 2001508441A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998530901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001508441A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/023482 external-priority patent/WO1998030240A1/en
Publication of JP2001508441A publication Critical patent/JP2001508441A/ja
Publication of JP2001508441A5 publication Critical patent/JP2001508441A5/ja
Ceased legal-status Critical Current

Links

JP53090198A 1997-01-10 1997-12-31 抗cd40l化合物での狼瘡腎炎の処置 Ceased JP2001508441A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3467397P 1997-01-10 1997-01-10
US60/034,673 1997-01-10
PCT/US1997/023482 WO1998030240A1 (en) 1997-01-10 1997-12-31 Treatment of lupus nephritis with anti-cd40l compounds

Publications (2)

Publication Number Publication Date
JP2001508441A JP2001508441A (ja) 2001-06-26
JP2001508441A5 true JP2001508441A5 (OSRAM) 2005-09-08

Family

ID=21877889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53090198A Ceased JP2001508441A (ja) 1997-01-10 1997-12-31 抗cd40l化合物での狼瘡腎炎の処置

Country Status (19)

Country Link
US (2) US20030031668A1 (OSRAM)
EP (2) EP1357131A3 (OSRAM)
JP (1) JP2001508441A (OSRAM)
KR (2) KR20000070034A (OSRAM)
CN (2) CN1572325A (OSRAM)
AU (1) AU5709798A (OSRAM)
BR (1) BR9714523A (OSRAM)
CA (1) CA2277222A1 (OSRAM)
CZ (1) CZ297680B6 (OSRAM)
EA (2) EA200501076A1 (OSRAM)
EE (1) EE9900273A (OSRAM)
HU (1) HUP0000833A3 (OSRAM)
IL (1) IL130784A0 (OSRAM)
IS (1) IS5100A (OSRAM)
NO (1) NO993274L (OSRAM)
NZ (1) NZ337072A (OSRAM)
PL (1) PL190663B1 (OSRAM)
TR (7) TR200001250T2 (OSRAM)
WO (1) WO1998030240A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
IL104684A0 (en) 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
HUP0101689A3 (en) * 1998-04-03 2004-08-30 Trustees Of Darmouth College H Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease
IL126681A0 (en) * 1998-10-21 1999-08-17 Opperbas Holding Bv Treatment of trauma-related conditions
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
ES2277460T3 (es) 1998-12-14 2007-07-01 Genetics Institute, Llc Cadena del receptor de la citoquina.
US6171795B1 (en) * 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
WO2001068133A1 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
AU8867501A (en) * 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
KR20040023565A (ko) * 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 B 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
ES2390344T3 (es) 2003-12-23 2012-11-12 Genentech, Inc. Tratamiento de cáncer con anticuerpos monoclonales anti-IL13 novedosos
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
CN100369932C (zh) * 2005-04-07 2008-02-20 苏州大学 抗人cd154单克隆抗体及其应用
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
US8435514B2 (en) 2008-12-05 2013-05-07 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
WO2012031122A2 (en) * 2010-09-03 2012-03-08 Immport Therapeutics, Inc. Methods and compositions for the diagnosis and treatment of cancer and autoimmune disorders
CN105722992B (zh) 2013-09-13 2021-04-20 豪夫迈·罗氏有限公司 用于检测和定量细胞系和重组多肽产物中的宿主细胞蛋白的组合物和方法
MY193481A (en) 2013-09-13 2022-10-17 Genentech Inc Method and compositions comprising purified recombinant polypeptides
JP2017525370A (ja) 2014-08-21 2017-09-07 ザ ジェネラル ホスピタル コーポレイション 腫瘍壊死因子スーパーファミリーおよびtnf様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびtnf様リガンドムテインを調製および使用する方法
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
JP2018526443A (ja) * 2015-08-31 2018-09-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 全身性エリテマトーデスを治療するためのlgals3bpの調節方法
IL322942A (en) 2017-05-24 2025-10-01 Als Therapy Development Inst Therapeutic anti-CD40 ligand antibodies
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
KR20230152032A (ko) 2021-02-03 2023-11-02 모차르트 쎄라퓨틱스 인코포레이티드 결합제 및 이를 사용하는 방법
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
WO1997026000A1 (en) * 1996-01-16 1997-07-24 The Trustees Of Columbia Univeristy In The City Of New York Therapeutic applications of t-bam (cd40-l) technology to treat inflammatory kidney diseases______________________________________
AU2593997A (en) * 1996-03-21 1997-10-10 Trustees Of Columbia University In The City Of New York, The Craf1 (traf-3) isoforms and uses thereof

Similar Documents

Publication Publication Date Title
JP2000511435A5 (OSRAM)
JP2000502280A5 (OSRAM)
JP2000501771A5 (OSRAM)
JP2000501599A5 (OSRAM)
JP2000500076A5 (OSRAM)
JP2000500055A5 (OSRAM)
JP2000500026A5 (OSRAM)
JP2000502472A5 (OSRAM)
JP2000501825A5 (OSRAM)
JP2000502425A5 (OSRAM)
JP2000502485A5 (OSRAM)
JP2000512956A5 (OSRAM)
JP2000502568A5 (OSRAM)
JP2000501774A5 (OSRAM)
JP2000502570A5 (OSRAM)
JP2000501876A5 (OSRAM)
JP2000501744A5 (OSRAM)
JP2000503984A5 (OSRAM)
JP2000502316A5 (OSRAM)
JP2000500857A5 (OSRAM)
JP2001508441A5 (OSRAM)
JP2000502714A5 (OSRAM)
JP2000501569A5 (OSRAM)
JP2000500184A5 (OSRAM)
JP2000500318A5 (OSRAM)